Document Type : Original Article

Authors

1 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Foreign Languages and Linguistics, Shiraz University, Shiraz, Iran

3 Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran

4 Non-communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

Abstract

Background: Much is still unknown regarding the clinicopathology and prognosis of patients with multifocal/multicentric breast cancer (MMBC). We herein compared the clinicopathology and prognosis of patients with unifocal and MMBCs.
Method: This cross-sectional research is a part of Shiraz Breast Cancer Registry (SBCR). We studied all the patients in the SBCR (n=6145). Ultrasound reports were used to differentiate between MMBCs and unifocal breast cancers (BCs). All the patients were examined with mammography and the diagnosis was confirmed postoperatively via pathology reports.
Results: After exclusion, 4045 patients entered the study (n=1072 and n=2973 for multifocal/multicentric and unifocal BCs, respectively). The mean follow-up period was 57.9 (0.27-275) months. Patients with MMBCs had higher rates of mastectomy (48% vs. 40.1%; P < 0.001) and higher rates of HER-2 overexpression (32.1% vs. 26%; P = 0.001) compared with those with unifocal BCs. Tumor size, lymph node involvement, type of axillary management, chemotherapy, radiotherapy, hormonal therapy, recurrence rates, histological grade, lymphovascular invasion, axillary node involvement, estrogen and progesterone receptor expression status, tumor, node, and metastasis staging were not significantly different between the groups. Five-year overall survival was 88.3% and 89% (P = 0.8) for unifocal and MMBCs, respectively; moreover, five-year disease-free survival was 80.2% and 81.2% (P = 0.41), respectively.
Conclusion: Despite the controversy regarding prognosis and surgical management in MMBCs, we found that MMBCs had similar clinicopathological features and prognosis compared to unifocal BCs. Survival, recurrence, and metastasis were similar among the two groups.

Keywords

How to cite this article:

Omidvar M, Tahmasebi S, Akrami M, Arasteh P, Zangouri V, Safaei A, et al. Survival, recurrence, and clinicopathological characteristics in multifocal and/or multicentric versus unifocal locoregional breast cancers: results of a large breast cancer registry. Middle East J Cancer. 2023;14(1):119- 26. doi: 10.30476/mejc.2022. 92135.1647.

  1. Fushimi A, Yoshida A, Yagata H, Takahashi O, Hayashi N, Suzuki K, et al. Prognostic impact of multifocal and multicentric breast cancer versus unifocal breast cancer. Surg Today. 2019;49(3):224-30. doi: 10.1007/s00595-018-1725-9.
  2. Setz-Pels W, Duijm LE, Groenewoud JH, Voogd AC, Jansen FH, Hooijen MJ, et al. Detection of bilateral breast cancer at biennial screening mammography in the Netherlands: a population-based study. Radiology. 2011;260(2):357-63. doi: 10.1148/radiol.11102117.
  3. Tot T. Axillary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: differences are related to macrometastatic disease. Ann Surg Oncol. 2012;19(11):3395-401. doi: 10.1245/s10434-012- 2346-y.
  4. Fang M, Zhang X, Zhang H, Wu K, Yu Y, Sheng Y. Local control of breast conservation therapy versus mastectomy in multifocal or multicentric breast cancer: A systematic review and meta-analysis. Breast Care (Basel). 2019;14(4):188-93. doi: 10.1159/000499439.
  5. Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, et al. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open. 2018;2(4):162-74. doi: 10.1002/bjs5.53.
  6. Bendifallah S, Werkoff G, Borie-Moutafoff C, Antoine M, Chopier J, Gligorov J, et al. Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol. 2010;19(4):e115-23. doi: 10.1016/j.suronc.2010.06.001.
  7. Neri A, Marrelli D, Megha T, Bettarini F, Tacchini D, De Franco L, et al. Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases. BMC Surg. 2015;15(1):1. doi: 10.1186/1471- 2482-15-1.
  8. Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, et al. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast J. 2015;21(2):121- 6. doi: 10.1111/tbj.12366.
  9. Winters ZE, Benson JR. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? Response to the preliminary alliance 11102 trial report. Ann Surg Oncol. 2019;26(2):700-1. doi: 10.1245/s10434-018- 6982-8.
  10. Nijenhuis MV, Rutgers EJ. Conservative surgery for multifocal/multicentric breast cancer. Breast. 2015;24 Suppl 2:S96-9. doi: 10.1016/j.breast.2015.07.023.
  11. Talei A, Tahmasebi S, Akrami M, Zangouri V, Rezaianzadeh A, Arasteh P, et al. The Shiraz Breast Cancer Registry (SBCR): study design and primary reports. Per Med. 2018;15(6):471-9. doi: 10.2217/pme- 2018-0047.
  12. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31): 3997-4013. doi: 10.1200/JCO.2013.50.9984.
  13. Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y, Davis AJ, et al. Tumor size and survival in multicentric and multifocal breast cancer. Breast. 2011;20(3):259-63. doi: 10.1016/j.breast.2011.01.005.
  14. Karakas Y, Dizdar O, Aksoy S, Hayran M, Altundag K. The effect of total size of lesions in multifocal/multicentric breast cancer on survival. Clin Breast Cancer. 2018;18(4):320-7. doi: 10.1016/j. clbc.2017.11.002.
  15. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, et al. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000;7(8):581-7. doi: 10.1007/ BF02725337.